Is AR-V7-positive status a contraindication to enzalutamide therapy?

According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard. … READ MORE …

COMET-1 trial does not show survival benefit … yet

Some in the investment community (and probably many in Exelixis itself) had been hoping that an interim analysis of an ongoing Phase III trial of cabozantinib (Cometriq) in the treatment of late-stage prostate cancer would show a positive outcome and allow the trial to be stopped early. … READ MORE …

AB Science initiates Phase III trial of masitinib in mCRPC, but …

A French company called AB Science has initiated a Phase III clinical trial of masitinib (yet another tyrosine kinase inhibitor) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

To prednisone or not to prednisone? Is that the question?

The past couple of years have seen a resurgence of academic (and clinical) interest in the value of the corticosteroid prednisone in combination with other drugs in the treatment of men with advanced forms of prostate cancer. … READ MORE …

Results of Phase III trial of custirsen (OGX-011) in mCRPC coming soon

According to a media release issued early this morning by OncoGenex Pharmaceuticals, the Phase III SYNERGY trial of custirsen (originally known as OGX-011) has reached its pre-specified endpoint in terms of the number of events required for final analysis of the trial data. … READ MORE …

Evaluating the risks and benefits of prednisone

Over the past 20 years or so, the oral corticosteroid prednisone has been used regularly in combination with drugs like mitoxantrone, docetaxel, cabazitaxel, ketoconazole, and abiraterone acetate in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Phase II trial of tasquinimod shows overall survival benefit

A paper in Clinical Cancer Research has reported an overall survival (OS) benefit of the investigational drug tasquinimod compared to a placebo in men with castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.

These data come from the long-term follow-up of the randomized Phase II trial of tasquinimod, and we shall have to wait for the results of the ongoing Phase III trial to confirm these results, but, according to this paper by Armstrong et al.:

  • Patients taking tasquinimod had a median OS of 33.4 months compared to 30.4 months for men treated with a placebo.
  • Patients whose cancer had already metastasized to their bones survived an average of 34.2 months, compared to 27.1 months for men treated with a placebo.

Additional information about this study can be found in a media release from the Duke University Health System; in an article on the OncLive web site; and in the actual paper by Armstrong et al.

It is worth remembering that few of the patients originally enrolled in this Phase II trial would have received either abiraterone acetate or enzalutamide prior to their initial treatment with either tasquinimod or the placebo, and that some of these patients may well have received abiraterone acetate or enzalutamide (or both) after their treatment with tasquinimod. It may be difficult, as a consequence, to know how much of the survival benefit shown in this trial is a direct consequence of treatment with tasquinimod itself. This is one of the reasons that the outcome of the later Phase III trial will be very important.

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

More data from the PREVAIL trial of enzalutamide

Data about the results of the Phase III PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) continue to dribble out ahead of the formal presentation … READ MORE …

Abstract of presentation about the PREVAIL trial of enzalutamide in mCRPC

The American Society of Clinical Oncology (ASCO) has released the abstract of the paper by Beer et al. to be presented in full at the upcoming Genitourinary Cancers Symposium in San Francisco late next week … but it doesn’t really tell us anything new. … READ MORE …

Response to enzalutamide as third-line treatment for mCRPC

According to a new article in Cancer, treatment with enzalutamide for men with metastatic, castration-resistant prostate cancer (mCRPC) after prior treatment with both docetaxel-based chemotherapy and abiraterone acetate demonstrated “modest” clinical activity. … READ MORE …

Patterns of treatment of European patients with CRPC in 2009-10

The full text of an article by Sternberg et al. (originally published in BMC Urology in 2013) has just been published to the Medscape Oncology web site and addresses patterns of treatment of men with castration-resistant prostate cancer (CRPC) in five European nations before wide availability of abiraterone. … READ MORE …

“Top pick” focuses on advances in treatment of mCRPC

In a new article on the Practice Update web site, Dr. Howard Scher, an oncologist specializing in treatment of advanced prostate cancer at Memorial Sloan-Kettering Cancer Center in New York, writes about his “top pick” regarding new prostate cancer knowledge from 2013. … READ MORE …

Full PREVAIL data to be presented at GU Oncology Symposium

On October 22, Medivation and Astellas Pharma had previously announced a positive result to the PREVAIL trial of enzalutamide vs. placebo in the treatment of men with chemotherapy-naive, metastatic castration-resistant prostate cancer. … READ MORE …

Moving forward by looking backward at men with CRPC

We may see some major shifts in the management of men with advanced forms of prostate cancer in the next few years. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers